Australia’s nutritional gummy market is expanding rapidly, but that growth also exposes a structural imbalance. According to Grand View Research, the category reached $251.3 million in 2023 and is projected to grow at a 15.8% CAGR from 2024 to 2030.
At the same time, the Complementary Medicines Australia (CMA) 2025 Industry Snapshot notes that Australia has 81 TGA-licensed complementary medicine manufacturing facilities … yet only a limited number are equipped for TGA-compliant gummy production, leaving a significant gap in regulated supply.
SIRIO Pharma is among the few suppliers capable of manufacturing TGA-compliant gummies. With facilities aligned with Australia’s TGA requirements, the company helps to address this shortage in regulated gummy manufacturing capacity.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.